Free Trial

Washington Trust Bank Has $15.10 Million Stock Holdings in Cencora, Inc. (NYSE:COR)

Cencora logo with Medical background

Washington Trust Bank lowered its holdings in Cencora, Inc. (NYSE:COR - Free Report) by 6.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 54,301 shares of the company's stock after selling 3,565 shares during the quarter. Cencora accounts for about 1.5% of Washington Trust Bank's investment portfolio, making the stock its 23rd biggest position. Washington Trust Bank's holdings in Cencora were worth $15,101,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Hoey Investments Inc. acquired a new position in Cencora in the first quarter valued at about $28,000. Banque Transatlantique SA acquired a new position in Cencora in the fourth quarter valued at about $29,000. SBI Securities Co. Ltd. acquired a new position in Cencora in the fourth quarter valued at about $30,000. Vermillion Wealth Management Inc. acquired a new position in Cencora in the fourth quarter valued at about $38,000. Finally, OFI Invest Asset Management acquired a new position in Cencora in the fourth quarter valued at about $41,000. Institutional investors own 97.52% of the company's stock.

Wall Street Analyst Weigh In

COR has been the topic of a number of recent analyst reports. Wells Fargo & Company upgraded shares of Cencora from an "equal weight" rating to an "overweight" rating and boosted their price target for the company from $274.00 to $337.00 in a research report on Tuesday, June 3rd. Jefferies Financial Group boosted their price target on shares of Cencora from $275.00 to $300.00 and gave the company a "hold" rating in a research report on Monday, June 30th. Morgan Stanley set a $288.00 price target on shares of Cencora in a research report on Tuesday, April 15th. Citigroup boosted their price target on shares of Cencora from $330.00 to $355.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. Finally, Robert W. Baird upped their target price on shares of Cencora from $314.00 to $350.00 and gave the stock an "outperform" rating in a research report on Thursday, May 8th. Two equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $306.33.

Read Our Latest Stock Analysis on COR

Insider Buying and Selling

In other Cencora news, Chairman Steven H. Collis sold 14,579 shares of the firm's stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $292.62, for a total value of $4,266,106.98. Following the transaction, the chairman directly owned 311,913 shares of the company's stock, valued at approximately $91,271,982.06. This trade represents a 4.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Robert P. Mauch sold 4,969 shares of the firm's stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $289.33, for a total transaction of $1,437,680.77. Following the completion of the transaction, the chief executive officer directly owned 47,582 shares in the company, valued at approximately $13,766,900.06. The trade was a 9.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 34,127 shares of company stock worth $9,812,296. Insiders own 10.80% of the company's stock.

Cencora Price Performance

Shares of COR traded down $4.43 during mid-day trading on Tuesday, hitting $298.07. 1,159,013 shares of the company traded hands, compared to its average volume of 1,508,757. Cencora, Inc. has a one year low of $218.65 and a one year high of $309.35. The company has a current ratio of 0.87, a quick ratio of 0.52 and a debt-to-equity ratio of 6.01. The business has a 50-day moving average of $291.57 and a 200 day moving average of $268.53. The stock has a market capitalization of $57.77 billion, a price-to-earnings ratio of 34.58, a PEG ratio of 1.50 and a beta of 0.57.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.07 by $0.35. Cencora had a net margin of 0.55% and a return on equity of 344.71%. The firm had revenue of $75.50 billion for the quarter, compared to analysts' expectations of $75.41 billion. During the same period last year, the firm earned $3.80 earnings per share. The business's revenue for the quarter was up 10.3% on a year-over-year basis. As a group, equities analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, June 2nd. Shareholders of record on Friday, May 16th were paid a $0.55 dividend. The ex-dividend date was Friday, May 16th. This represents a $2.20 dividend on an annualized basis and a yield of 0.74%. Cencora's payout ratio is presently 25.52%.

Cencora Profile

(Free Report)

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

Further Reading

Institutional Ownership by Quarter for Cencora (NYSE:COR)

Should You Invest $1,000 in Cencora Right Now?

Before you consider Cencora, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.

While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Made in America Stocks Under $20 You Need to See!
3 Cheap Growth Stocks Set to Explode This Summer
The Next NVIDIA? Quantum Computing Stocks Set for Explosive Growth

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines